Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03071705
Recruitment Status : Unknown
Verified March 2017 by Oscar Gerardo Arrieta Rodríguez MD, Instituto Nacional de Cancerologia de Mexico.
Recruitment status was:  Recruiting
First Posted : March 7, 2017
Last Update Posted : March 7, 2017
Information provided by (Responsible Party):
Oscar Gerardo Arrieta Rodríguez MD, Instituto Nacional de Cancerologia de Mexico

Brief Summary:

Treatment for patients with mutation in the epidermal growth factor receptor (EGFR) with specific domain tyrosine kinase inhibitors (TKIs) has given place to objective clinical response, increase in progression-free survival (PFS) compared to cytotoxic chemotherapy. However, despite clinical success with different TKIs, most patients eventually develop acquired resistance to these agents after an average period of time of 10 months.

Recently metformin, an oral hypoglycemic agent, has been associated with reduction in the global risk of incidence and mortality of different types of cancer, by exercising anti-tumor properties. Its role as a chemo-preventive and adjuvant drug in overcoming acquired resistance to chemotherapy, target therapy and immunotherapy in NSCLC is still under discussion.

However, preclinical data support the role as an adjuvant drug in the treatment of NSCLC in combination with chemotherapy or EGFR-TKIs. This evidence led to examine the effects of metformin in combination with EGFR-TKIs in a NSCLC cellular line panel, obtaining a different sensibility to the unique use with EGFR-TKIs. The combination of metformin and TKIs reduced the colony forming capacity and proliferation, and induced a huge pro-apoptotic effect in NSCLC cellular lines and resistance in EGFR-TKIs. This suggests that metformin may reduce the resistance to TKIs. A retrospective study in patients from our institution from 2008 to 2014, showed significant clinical benefit in patients who used metformin, improving the global survival. Based on these considerations, we propose a phase II randomized study to assess the effect and safety of metformin in combination with TKIs as second line therapy in patients with NSCLC in advanced stages with EGFR mutation.

The main objective of this study is to assess the progression-free survival period in patients with advanced non-small cell lung cancer in treatment with TKIs and metformin versus TKI alone.

Condition or disease Intervention/treatment Phase
Non-Small Cell Adenocarcinoma Tyrosine Kinase Mutation EGFR Gene Mutation Drug: Metformin Drug: TKI Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: Effect of Metformin in Combination With Tyrosine Kinase Inhibitors (TKI) on Clinical, Biochemical and Nutritional in Patients With Non-Small Cell Lung Carcinoma (NSCLC): Randomized Clinical Trial
Study Start Date : March 2016
Estimated Primary Completion Date : April 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intervention
TKI plus Metformin
Drug: Metformin
500 mg PO BID
Other Name: DABEXR

Drug: TKI
standard dose
Other Names:
  • erlotinib
  • afatinib
  • gefitinib

Active Comparator: Control
Drug: TKI
standard dose
Other Names:
  • erlotinib
  • afatinib
  • gefitinib

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Start of treatment until 1-year follow-up ]

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: 3 month evaluation after start of treatment ]
    Inflammatory markers (IL-6, IL-12, TNF-alpha)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • NSCLC EGFR mutation-positive
  • Use of only Metformin as oral hypoglucemic agent
  • ECOG-PS 0-2
  • Measurable disease
  • Life expectancy >12 weeks

Exclusion Criteria:

  • Systemic disease
  • Patients with TKI treatment longer than 2 months
  • History of other neoplasm in the past 5 years
  • Breastfeeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03071705

Layout table for location contacts
Contact: Oscar Arrieta, MD, MSc 01 55 5628 0400 ext 71100

Layout table for location information
Instituto National de Cancerologia Recruiting
Mexico, Mexico, 14080
Contact: Oscar Gerardo MD Arrieta, Oncology    015556280400 ext 71101   
Sponsors and Collaborators
Instituto Nacional de Cancerologia de Mexico
Layout table for investigator information
Study Director: Oscar Arrieta, MD, MSc Instituto Nacional de Cancerología
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oscar Gerardo Arrieta Rodríguez MD, Head Thoracic Oncology Unit, Instituto Nacional de Cancerologia de Mexico Identifier: NCT03071705    
Other Study ID Numbers: 016/018/ICI
Ethics Committe ( Other Identifier: CEI/1019/16 )
First Posted: March 7, 2017    Key Record Dates
Last Update Posted: March 7, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Data will be uploaded to a repository in an anonimized manner to preserve patient confidentiality.
Keywords provided by Oscar Gerardo Arrieta Rodríguez MD, Instituto Nacional de Cancerologia de Mexico:
metformin plus TKI
EGFR positive status
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action